Drug Profile
AAA 135
Latest Information Update: 30 Apr 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Heart failure therapies
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 04 Feb 1998 New profile
- 04 Feb 1998 Investigation in Ischaemic heart disorders in Canada (Unknown route)
- 04 Feb 1998 Preclinical development for Heart failure in Canada (Unknown route)